Presumed case of “stiff-horse syndrome” caused by decreased gamma-aminobutyric acid (GABA) production in an American Paint mare.

The study presents a case of ‘stiff-horse syndrome’ in an American Paint mare, which was presumably caused by decreased production of gamma-aminobutyric acid (GABA). Treatment with dexamethasone led to the resolution of clinical symptoms and decrease in Glutamic Acid Decarboxylase (GAD) antibody concentrations, supporting the hypothesis of the syndrome’s origin.

Background and Purpose of The Research

• In this manuscript, a specific case of the “stiff-horse syndrome” in an American Paint mare is presented. This disease is characterized by an increase in postural muscle tone that results in stiffness and recumbency in the animal.
• The purpose of the researchers was to identify the cause of this syndrome and find an effective treatment for it.

Methodology

• The researchers established that Glutamic Acid Decarboxylase (GAD), an enzyme that converts glutamic acid into gamma-aminobutyric acid (GABA), plays a critical role in the syndrome’s pathogenesis.
• They tested the mare’s serum and found increased concentrations of GAD autoantibodies, indicating autoimmune activity.

Results

• The researchers treated the mare with dexamethasone, a type of corticosteroid medication often used to treat inflammatory conditions.
• After the treatment, clinical symptoms related to the ‘stiff-horse syndrome’, such as stiffness and recumbence, were resolved.
• Additionally, the concentrations of GAD autoantibodies in the mare’s serum significantly decreased after the treatment, suggesting a link between the disease’s manifestations and the presence of these antibodies.

Conclusion and Implications

• The study confirmed that ‘stiff-horse syndrome’ might be a consequence of decreased GABA production, as suggested by the high levels of GAD autoantibodies in the mare’s serum.
• The successful treatment with dexamethasone and the subsequent improvement of the mare’s condition support this conclusion.
• The findings have important implications for the diagnosis and management of the “stiff-horse syndrome”.
• Identifying this syndrome as a consequence of a GABA production problem offers a new perspective on its origin that could help develop more effective treatments in the future.